Tanespimycin Price Trend and Forecast
Get the latest insights on price movement and trend analysis of Tanespimycin in different regions across the world (Asia, Europe, North America, Latin America, and the Middle East & Africa).
Tanespimycin Price Trend for Q1 of 2025
During Q1’25, Tanespimycin prices showed a notable rebound across global markets after the sustained downward trend throughout 2024. The first quarter saw prices climb steadily as pharmaceutical manufacturers strategically limited production while demand from oncology treatment centres began to strengthen.
Tanespimycin Price Chart
Please Login or Subscribe to Access the Tanespimycin Price Chart Data
In North American markets, prices rose more aggressively than anticipated, influenced partly by changing trade dynamics following new tariff implementations. Manufacturers responded by holding back inventory, creating tighter supply conditions that supported the price recovery. Supply chain stakeholders reported increasing procurement challenges by late February.
Asian markets, particularly in China and India, experienced similar upward price movements, though with more regional variation. Production costs were impacted by agricultural feedstock volatility, as key raw material inputs used in Tanespimycin synthesis became more expensive. The correlation with agricultural commodity markets became evident as tightening corn supplies and farmers' reluctance to sell at lower prices affected the cost structure of pharmaceutical precursors.
European buyers faced steeper price increases than other regions during this period due to additional logistical complications and transportation costs. Pharmaceutical manufacturers cited narrowing margins throughout 2024 as justification for the Q1 price adjustments.
Analyst Insight
According to Procurement Resource, the current price rebound in Tanespimycin market is expected to continue through Q2, though sustainability remains uncertain as new production capacity could come online and agricultural feedstock markets stabilize.
Tanespimycin Price Trend for the Year 2024
Throughout 2024, Tanespimycin prices followed a consistently downward trajectory across all major markets. The first half of the year saw moderate price declines as pharmaceutical manufacturers adjusted to changing demand patterns in oncology treatments. By Q3, the price erosion accelerated due to increased competition from alternative therapies and growing availability of manufacturing capacity.
In Asia, particularly China and India, Tanespimycin experienced sharper price drops compared to other regions. This was partially influenced by agricultural commodity markets, as corn (a key raw material feedstock in the production chain) faced significant oversupply issues. The feedstock cost advantages failed to offset weakening demand in the region's pharmaceutical sector.
European markets showed similar trends but with less volatility. Manufacturing challenges and higher transportation costs temporarily stabilized prices midyear, but the overall movement remained downward as hospital procurement budgets tightened.
North American prices declined more gradually than other regions during Q4, supported by strategic inventory management by major pharmaceutical companies. However, increased production efficiency and favorable raw material costs eventually pushed prices lower by year-end.
Analyst Insight
According to Procurement Resource, Tanespimycin prices are expected to stabilize by mid-2025 as supply and demand reach equilibrium, though any breakthrough oncology applications could quickly reverse this trend.
Tanespimycin Price Trend for the Second Half of 2023
Since fermentation of carbohydrate sources like corn and starch is involved in the production of the antibiotic drug Tanespimycin, the prices also depend on the feedstock corn prices. The prices were almost stable during the third quarter as the feedstock prices didn’t vary much, and the downstream demands also maintained a steady curve.
However, a sudden dip in the feedstock prices in the following quarter affected the upstream dynamics of the Tanespimycin market. Production costs declined, which resulted in the marginal wavering of the prices as well. However, since the pharma industry is one of the most regulated and watched industries, the policies and incentives related to it also influence the market prices, so largely stable market dynamics were witnessed.
Analyst Insight
According to Procurement Resource, Tanespimycin price trends are likely to vacillate within confined limits going forward as well. Not much change is anticipated in the Tanespimycin market.
Tanespimycin Price Trend for the First Half of 2023
Tanespimycin is an antibiotic drug derived from corn via fermentation. So, the prices depend a lot on the feedstock corn prices. Corn prices fluctuated throughout the said period of H1 2023. Prices were on the upper side during the first quarter in Asia and Europe as the Ukrainian supplies were curtailed and the production yields were low. Prices showed some temporary reverse fluctuations in the USA but were set on a declining trajectory in Q2 owing to sullen market demands.
The Black Sea Treaty between Russia, Ukraine, and the United Nations gave access to Ukrainian supplies raising the supply levels. However, the market offtakes still stayed low as the demands dipped, constantly affecting the overall price trend for Tanespimycin and other corn-derived products.
Analyst insight
According to Procurement Resource, the Tanespimycin prices are expected to continue fluctuating in a similar manner as the market demands do not seem to be picking up anytime soon.
Procurement Resource provides latest prices of Tanespimycin. Each price database is tied to a user-friendly graphing tool dating back to 2014, which provides a range of functionalities: configuration of price series over user defined time period; comparison of product movements across countries; customisation of price currencies and unit; extraction of price data as excel files to be used offline.
Tanespimycin is a benzoquinone antineoplastic antibiotic obtained from geldanamycin. It belongs to the class of antitumor antibiotics and is currently being studied in cancer treatment. It binds and inhibits the oncogenic signaling proteins HSP90, expressed in tumour cells. It is studied for the treatment of leukaemia, kidney tumors, etc.
Report Features | Details |
Product Name | Tanespimycin |
CAS Number | 75747-14-7 |
Industrial Uses | Pharmaceuticals, Research Studies |
Chemical Formula | C31H43N3O8 |
Synonyms | 17-N-Allylamino-17-demethoxygeldanamycin, 17-AAG |
Molecular Weight | 585.69 g/mol |
Supplier Database | Kosan Biosciences (Bristol-Myers Squibb) |
Region/Countries Covered | Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Iran, Thailand, South Korea, Iraq, Saudi Arabia, Malaysia, Nepal, Taiwan, Sri Lanka, UAE, Israel, Hongkong, Singapore, Oman, Kuwait, Qatar, Australia, and New Zealand Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru Africa: South Africa, Nigeria, Egypt, Algeria, Morocco |
Currency | US$ (Data can also be provided in local currency) |
Supplier Database Availability | Yes |
Customization Scope | The report can be customized as per the requirements of the customer |
Post-Sale Analyst Support | 360-degree analyst support after report delivery |
Note: Our supplier search experts can assist your procurement teams in compiling and validating a list of suppliers indicating they have products, services, and capabilities that meet your company's needs.
Tanespimycin is produced via fermentation of corn via multiple-step fermentation in fermenting reactors.
The displayed pricing data is derived through weighted average purchase price, including contract and spot transactions at the specified locations unless otherwise stated. The information provided comes from the compilation and processing of commercial data officially reported for each nation (i.e. government agencies, external trade bodies, and industry publications).
Procurement Resource is a one-stop solution for businesses aiming at the best industry insights and market evaluation in the arena of procurement. Our team of market leaders covers all the facets of procurement strategies with its holistic industry reports, extensive production cost and pre-feasibility insights, and price trends dynamics impacting the cost trajectories of the plethora of products encompassing various industries. With the best analysis of the market trends and comprehensive consulting in light of the best strategic footstep, Procurement Resource got all that it takes.
Procurement Resource has made a mark for itself in terms of its rigorous assistance to its clientele. Our experienced panel of experts leave no stone unturned in ensuring the expertise at every step of our clients' strategic procurement journey. Our prompt assistance, prudential analysis, and pragmatic tactics considering the best procurement move for industries are all that sets us apart. We at Procurement Resource value our clients, which our clients vouch for.
Expertise, judiciousness, and expedience are the crucial aspects of our modus operandi at Procurement Resource. Quality is non-negotiable, and we don't compromise on that. Our best-in-class solutions, elaborative consulting substantiated by exhaustive evaluation, and fool-proof reports have led us to come this far, making us the ‘numero uno' in the domain of procurement. Be it exclusive qualitative research or assiduous quantitative research methodologies, our high quality of work is what our clients swear by.
Phone:+1 307 363 1045
Phone: +91 8850629517
Phone: +44 7537 171117
Email: sales@procurementresource.com